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Post-translational modiﬁcationO-Linked N-acetylglucosamine transferase (OGT) was identiﬁed as an Nrf1-interacting protein.
Herein, we show that Nrf1 enables interaction with OGT and their co-immunoprecipitates are
O-GlcNAcylated by the enzyme. The putative O-GlcNAcylation negatively regulates Nrf1/TCF11 to
reduce both its protein stability and transactivation activity of target gene expression. The turnover
of Nrf1 is enhanced upon overexpression of OGT, which promotes ubiquitination of the CNC-bZIP
protein. Furthermore, the serine/theorine-rich sequence of PEST2 degron within Nrf1 is identiﬁed
to be involved in the protein O-GlcNAcylation by OGT. Overall, Nrf1 is negatively regulated by its
O-GlcNAcylation status that depends on the glucose concentrations.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Glycosylation and deglycosylation are a pair of ubiquitous rever-
sible modiﬁcations of proteins contributing to numerous biological
functions in all systems of life [1–3]. A glycomic estimate suggests
that over 50% of all proteins are glycosylated by the covalent attach-
ment of P7,000 glycans to polypeptide structures through amide
linkages (i.e. N-glycosylation) to asparagine side chains, through
glycosidic linkages (i.e. O-glycosylation) to side chains of serine
and/or threonine, hydroxylysine (e.g. collagen) or tyrosine residues
(e.g. glycogenin), or through C–C linkages (i.e. C-glycosylation) to the
C2 position of tryptophan [4]. This estimate is also thought to be far
too low, because it does not consider that many, if not most, pro-
teins within the nucleus and cytoplasm are dynamically modiﬁed
by the attachment of b-D-N-acetylglucosamine (GlcNAc) moieties
to the hydroxyl group of serine and/or threonine residues (i.e.
O-GlcNAcylation) [5]. The unique O-GlcNAcylation of such soluble
nucleocytoplasmic proteins, as well as secreted or membrane glu-
coproteins, occurs in response to cell biological or environmental
cues, including growth factors, signaling molecules, glucose and
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O-GlcNAcylation is of paramount importance in the regulation of
cellular metabolism, signaling, transcription, and other processes
[6,7]. Conversely, dysregulation of O-GlcNAcylation contributes to
the etiology of cancer, diabetes, neurodegenerative and inﬂamma-
tory diseases [8–11].
The O-GlcNAcylation reaction is catalyzed by O-linked
N-acetylglucosamine transferase (OGT, encoded by the Ogt/Sxc
gene residing in close proximity to the XIST locus [12,13]), which
enables the transfer of a single O-GlcNAc moiety from uridine dis-
phosphate N-acetylglucosamine (UDP-GlcNAc) to a serine or thre-
onine residue of protein substrates, whilst removal of the
O-GlcNAc (i.e. de-GlcNAcylation) is catalyzed by O-GlcNAcase
(OGA, encoded by the single Oga/MGEA5 gene) [14,15]. The
O-GlcNAc cycling is mediated by OGT (with three alternatively
spliced isoforms of 106kDa, 103kDa and 74.5kDa) and OGA (with
two spliced isoforms of 130kDa and 75kDa); both are per se
modiﬁed by O-GlcNAcylation in metazoan animals [16,17]. The
enzymatic activity of OGT and its substrate speciﬁcity are
dependent on concentrations of UDP-GlcNAc, which is controlled
by several major metabolic pathways in response to stimuli and
nutrient availability (Fig. 1A). Generally, 2–5% of glucose that
enters the cell is via the glycolytic pathway to produce
fructose-6-phosphate (Fruc-6-p) committed to the hexosamine
biosynthetic pathway (HBP) to make UDP-GlcNAc as an end prod-
uct. The HBP ﬂux is also integrated with metabolisms of amino
acids, fatty acids and nucleotides. Glutamine (Gln) serves as the
nitrogen donor to form glucosamine-6-phosphate (GlcNH2–6-p),
the latter acetylation reaction occurs by catalytically trans-
ferring the acetyl group from the donor acetyl-CoA to yield
N-acetylglucosamine-6-phosphate (GlcNAc-6-p), and subsequent
cascade reactions with the uridine trisphosphate (UTP) promotes
biosynthesis of UDP-GlcNAc. Collectively, UDP-GlcNAc is well
placed at a major nexus between cellular metabolic networks
and signaling responsive pathways.
O-GlcNAcylation is abolished by disruption of Ogt, leading to
the lethality of XY stem cells from male mice and resulting embry-
onic lethality at 5.5 days post-coitus [18]. Loss of the essential
function of OGT for O-GlcNAcylation in early development of ver-
tebrate is also accompanied by a series of dramatic effects on cel-
lular metabolism, signaling, transcription, gene expression, and
adaptation in response to various pathophysiological cues
[6,7,17]. It is well deﬁned that the nutrient-sensitive OGT is
allowed for gene regulation by interacting and modifying key
transcriptional factors (e.g. c-Myc, p53, FoxO1, CREB, CRTC2,
HCF1, PPARc, ERb, OCT4, NANOG, SOX2, SIN3A and ZFP281), and
epigenetic regulators (e.g., PcG, TrxG, HDAC and NCOR2), as well
as C-terminal domain of the RNA polymerase II, to promote the
assembly of distinct functional coding machineries. Interestingly,
amongst over 1,000 substrates of OGT, only an evolutionary
conserved transcriptional co-activator called host cell factor 1
(HCF1) undergoes an unusual proteolytic cleavage to produce
both its N-terminal and C-terminal subunits (i.e. HCF1N and
HCF1C, that are involved in control of the cell cycle at G1 and
M1 phases, respectively), in the process whereby OGT is
considered to act as a novel protease involving the
O-GlcNAcylation reaction [19].
Recently, the O-GlcNAcylation enzyme OGT, as well as its sub-
strates HCF1 and casein kinase 2 (CK2), had also been detected
as one of nuclear factor-erythroid 2 (NF-E2) p45-related factor 1
(Nrf1)-interacting proteins by liquid chromatography-mass spec-
trometry (LC–MS)/MS (see Supplemental data from [20]).
However, it is unknown whether OGT mediates O-GlcNAcylation
of Nrf1 and its long isoforms TCF11 (transcription factor 11). The
latter two proteins belong to the family of cap’n’collar (CNC) basic
region-leucine zipper (bZIP) transcription factors that control avariety of critical homeostatic and developmental pathways
through regulating the expression of antioxidant response element
(ARE)-driven genes, encoding antioxidant proteins, detoxiﬁcation
enzymes, metabolic enzymes and 26S proteosomal subunits [21–
23]. The CNC-bZIP family comprises the Drosophila Cnc protein,
the Caenorhabditis elegans skinhead-1 (Skn-1), the vertebrate acti-
vator NF-E2 p45 and related Nrf1 (including TCF11 and its short
form LCR-F1/Nrf1b), Nrf2 and Nrf3, as well as the transcription
repressors Bach1 (BTB and CNC homolog 1) and Bach2. In mam-
mals, Nrf1 and Nrf2 are two principal CNC-bZIP factors to regulate
ARE-driven cytoprotective genes against cellular stress [24,25].
However, a sharp distinction between Nrf1 and Nrf2 is deﬁned
by the ﬁndings that the soluble Nrf2 is dispensable for develop-
ment [26], whereas the membrane-bound Nrf1 is essential for
maintaining cellular homeostasis and organ integrity during
development and growth. The latter conclusion is drawn from
gene-targeting experiments showing that global knockout of Nrf1
(also called nfe2l1) in mice causes embryonic lethality and severe
oxidative stress [27–29] and speciﬁcally conditional knockout of
the gene in the liver and brain results in non-alcoholic steatohep-
atitis, hepatoma [30,31] and neurodegeneration [32,33].
The unique biological function of Nrf1 is dictated by its
membrane-topovectorial processing within and around endoplas-
mic reticulum (ER) to produce several isoforms through different
post-translational modiﬁcations [34–39]. Upon translation of
Nrf1, its uncleavable N-terminal signal sequence (called NHB1)
enables the nascent protein to be integrated in a speciﬁc topology
within and around the ER. After Nrf1 is anchored within the ER
membrane through the NHB1-associated region, its connecting
transactivation domains (TADs, including AD1, NST and AD2) are
transiently translocated into the lumen, where Nrf1 is
N-glycosylated by the covalent attachment of the glycan
Glc3Man9GlcNAc2 through amide linkages to asparagine residues
in the central Asn/Ser/Thr-rich (NST) domain, enabling Nrf1 to
represent an inactive 120kDa glycoprotein. Subsequently, glycosy-
lated NST-containing TADs are allowed for dynamic repartitioning
out of the ER and repositioning into the cyto/nucloplasm,
whereupon Nrf1 is deglycosylated to yield an active 95kDa factor
because its TADs can gain access to the general transcriptional
machinery, enabling target gene transactivation. The membrane-
topovectorial organization of Nrf1 also dictates selective
proteolytic processing of the CNC-bZIP protein to generate distinct
isoforms of between 85kDa and 25kDa that differentially regulate
ARE-battery genes [37,39–41]. In the present study, we have
investigated whether and how the protein stability of Nrf1 is
inﬂuenced by OGT-mediated O-GlcNAcylation. The resultant
evidence that has been presented here demonstrates that the
putative O-GlcNAcylation of Nrf1 negatively regulates the
constitutive expression of the CNC-bZIP factor, its protein stability
and its transactivation activity to down-regulate ARE-driven target
genes.
2. Materials and methods
2.1. Chemicals, antibodies and other regents
All chemicals were of the highest quality commercially avail-
able, of which Alloxan (as an OGT-speciﬁc inhibitor), PUGNAc (as
an OGA-speciﬁc inhibitor), MG132 (as a pan proteasomal inhibitor)
and cycloheximide (CHX, which blocks nascent polypeptide
biosynthesis) were purchased from Sigma–Aldrich (St Louis, MO,
USA). Two antibodies against the glycan O-GlcNAc epitope
(CTD110.6) and TCF11/Nrf1 (D5B10) were obtained from Cell
Signaling Technology (Bedford, MA, USA). Antibodies against OGT
(H-300) were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Antibodies against each of the Flag, V5, HA and GST epitopes,
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Fig. 1. Expression of human Nrf1/TCF11 is inﬂuenced by the intracellular status of O-GlcNAc that depends on the glucose (Glc) concentrations. (A) Schematic representation
of the hexosamine biosynthetic pathway (HBP) to yield UDP-GlcNAc and subsequent cycling of O-GlcNAc. The cycling enzymes OGT and OGA control a pair of reversible
modiﬁcations: O-GlcNAcylation and ensuing de-GlcNAcylation, respectively. Of importance is that O-GlcNAcylation has been considered as a nutrient sensor because the
donor sugar, UDP-GlcNAc, integrates inputs frommultiple metabolic pathways. The OGT activity to transfer the monosaccharide GlcNAc to serine/threonine residues depends
upon UDP-GlcNAc concentrations. The enzymatic activity of OGT can be inhibited by Alloxan, whilst PUGNAc is an inhibitor of the OGA that hydrolyses the sugar O-GlcNAc to
be removed from substrates. Upon addition of GlcNH2, it is enabled to directly enter the HBP ﬂux. All abbreviations were deﬁned in the main text. (B) HEK293T cells were
allowed to be grown in a hypoglucose medium (containing 5 mmol/L glucose) and also treated with 100 lmol/L Alloxan for 6 h. The total cell lysates were subjected to
separation of proteins by SDS–PAGE containing 8% polyacrylamide, followed by Western blotting with antibodies against O-GlcNAc and Nrf1/TCF11. In addition, tubulin
served as the internal control for loading proteins. The intensity of blots was quantiﬁed by using the ImageJ software and normalized to the control value. (C) HEK293T cells
were allowed to be grown in a hyperglucose medium (containing 25 mmol/L glucose) and treated with 50 lmol/L PUGNAc for 6 h. Subsequently, the total cell lysates were
subjected to separation of proteins by SDS–PAGE containing 10% polyacrylamide, followed by Western blotting and quantiﬁcation of the blot intensity by densitometry as
described above.
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were from Signalway Antibody (College Park). The GST-based
Protein Interaction Pull-Down Kit was purchased from Thermo sci-
entiﬁc. Both SYBR Green universal master mix and Multiscript RT
were from TaKaRa Biotechnology Co., Ltd (Dalian, China).2.2. Plasmids and siRNAs
Two expression constructs for GST-OGT fusion protein
(pGEX-OGT) and its mutant [pcDNA-OGTD(TPR1-6)] [42], together
with the free-GST expression plasmid pGEX-4T, were a kind gift
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University). The plasmid pcDNA-Flag-OGT (#29760) and the
pRL-CMV reporter were purchased from Addgene and Promega,
respectively. Additional expression constructs for Nrf1 and its
mutant that had been created on the base of pcDNA3.1/V5His, as
well as pcDNA-3  HA-Ub and the ARE-driven reporter gene
PSV406  ARE-GSTA2-Luc, were developed in our laboratory
[34–39]. All these constructs were veriﬁed by DNA sequencing.
Two sequences of small interfering RNAs (siRNAs): 50-GGAGCCUU
GCAGUGUUAUA-30 and 50-GAGGCAGUUCGCUUGUAUCGU-30,
target against the human OGT mRNA coding region so as to
knockdown its expression. In addition, a scrambled siRNA
sequence (5’-UUCUCCGAACGUGUCACG-3’) that has no homology
with any genes was used as an internal negative control.
2.3. Cell culture and transfection
Human embryonic kidney (HEK293T) cell lines were main-
tained in the State Key Laboratory of Cancer Biology, the Fourth
Military Medical University. The cells were grown in Dulbecco’s
Modiﬁed Eagle Medium (DMEM, from Gibco BRL, Grand Island,
NY, USA) supplemented with 10% fetal bovine serum (FBS, from
Gibco BRL), 100 U/ml penicillin and 100 lg/ml streptomycin (both
from Invitrogen, Carlsbad, CA, USA) in a 37 C incubator with 5%
CO2 in the humidiﬁed air. These cells were subjected to
transfection experiments that had been conducted by using
TurboFect Transfection Reagent (from Thermo Scientiﬁc) following
the manufacturer’s instructions.
2.4. Quantitative real-time PCR analysis
HEK293T cells that had been transfected with the indicated
siRNAs were subjected to isolation of total RNAs, which were
carried out by using the RNAiso kit (from Takara) according to
the manufacturer’s instructions. Subsequently, 500 ng of total
RNAs was added in retrotranscription reaction with the
PrimeScript RT Master Mix (from TaKaRa) to generate the ﬁrst
strand of cDNA, which served as the template for qRT-PCR that
was performed in the following conditions: activation at 95 C
for 30 s, followed by 40 cycles of 10 s at 95 C, and 30 s at 58 C.
At last, the melting curve was added to examine the ampliﬁcation
quality. Expression of mRNA for b-actin was used as an internal
control standard. Two pairs of primers used were as follows:
OGT with 50-GGCAGTTCGCTTGTATCGT-30 (forward) and 50-GATG
GCACGCGTATAACAC-30 (reverse) sequences, and b-actin with
50-AATCTGGCACCACAC CTT CTACAA-30 (forward) and 50-TAGCAC
AGCCTGGATAGCAACG-30 (reverse) sequences.
2.5. Western blotting with O-GlcNAcylation analysis
Experimental cells were either treated with the indicated chem-
icals or transfected with distinct expression constructs before
being harvested and homogenized in RIPA lysis buffer (50 mM
Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS) containing 2 lg/mL protease inhibitor cocktail (from
Roche, Germany). The clariﬁed supernatants were collected and
then the protein concentrations were determined by using a BCA
protein assay kit (from Pierce Biotechnology, Rockford, IL, USA).
Equal amounts (20 lg) of protein extracts were subjected to elec-
tropherotic separation by SDS–PAGE containing 6% to 10% poly-
acrylamide. Subsequently, the resolved proteins were transferred
onto the Amersham’s nitrocellulose membranes, followed by
Western blotting with distinct primary and secondary antibodies.
The protein-transferred membranes were blocked by incubation
with 5% bovine serum albumin at room temperature for 1 h and
was then re-incubated with each of the primary antibodies forovernight at 4 C. Thereafter, the antibody blots were
cross-reacted for 1 h with the corresponding species-speciﬁc sec-
ondary antibodies, followed by visualization by using either the
enhanced chemiluminescence or the Odyssey Imaging System
(Li-Cor Biosciences). The intensity of immunoblotted protein bands
was quantiﬁed by using the ImageJ software, and normalized to
distinct protein-loading and other controls as described in ﬁgure
legends. Amongst the primary antibodies, O-GlcNAc-speciﬁc anti-
body (CTD110.6) was used to detect the O-GlcNAcylation status
of protein substrates of OGT [42].
2.6. Co-immunoprecipitation and ubiquitination assays
HEK293T cells had been grown on 10-cm dishes, and trans-
fected for 48 h with each (20 lg of DNA) of expression constructs
for OGT, Nrf1 and their mutants. The cells were treated with
10 lM MG132 for an additional 4 h before being harvested in lysis
buffer: 50 mM Tris, pH 8.0, 20% glycerol, 500 mMNaCl, 0.5% NP-40,
5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 1 mM PMSF, 1  protease
inhibitors (from Roche). The supernatants collected from centrifu-
gation were pre-clariﬁed by the protein A/G PLUS-agarose (from
Santa Cruz Biotechnology) for 40 min at 4 C, followed by immuno-
precipitation with antibodies against the V5 epitope or the normal
mouse IgG overnight at 4 C. The precipitates were re-incubated
with the protein A/G PLUS-agarose for 6 h and then washed ﬁve
times with the buffer: 50 mM Tris, pH 7.5, 10% glycerol, 100 mM
NaCl, 0.1% NP-40, 1 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, before
being subjected to protein resolution by SDS–PAGE, followed by
Western blotting analysis. For in vivo ubiquitination assay, the cells
were co-transfected with HA-tagged ubiquitin (Ub) and/or each of
the indicated expression constructs for 48 h, before being treated
with 10 lM MG132 for 4 h. The cell lysates were subjected to
co-immunoprecipitation with a V5 antibody, and immunoblotting
with antibodies against the HA epitope or the O-GlcNAc glycan to
detect the status of ubiquitination [43] or O-GlcNAcylation [42].
2.7. GST-based pull-down assay
Expression of GST or its fusion protein with OGT (i.e. GST-OGT)
was induced by 0.2 mmol/L IPTG in Escherichia coli BL21 (DE3,
pLys), before they were immobilized on glutathione-agarose by
using the GST Protein Interaction Pull-Down Kit (from Thermo sci-
entiﬁc), which was carried out according to the manufacturer’s
instructions. HEK293T cells were transfected with expression con-
structs for Nrf1, before being incubated with equal amounts of
immobilized GST or its fusion proteins for 16 h at 4 C. The
GST-bound agarose beadswerewashed ﬁve timeswith awash solu-
tion enclosed in the kit, before GST-bound proteins were eluted,
separated by SDS–PAGE, and then visualized by Western blotting.
2.8. Luciferase reporter assay
Cells were co-transfected with 200 ng of ARE-driven luciferase
reporter (PSV406  ARE-GSTA2-Luc) and 20 ng of renilla luciferase
reporter (pRL-CMV), along with siRNA or other effecter plasmids
as required. At 24 h after transfection, the reporter activity was
measured by using the dual luciferase reporter assay system
(E1910 from Promega), according to the manufacturer’s instruc-
tion, and then was normalized to the value of corresponding renilla
luciferase activity. Subsequently, differences in their transcrip-
tional activity were subjected to statistical analyses.
2.9. Cycloheximide chase experiment
HEK293T cells had been transfected with the indicated siRNAs,
and 24 h latter were subjected to cycloheximide (CHX, 100 lg/ml)
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0.5, 1, 2 and 4 h). Subsequently, the cell lysates were examined by
Western blotting experiments to assess the protein stability of Nrf1
and OGT.
2.10. Statistical analysis
The statistical signiﬁcance of changes in the ARE-driven repor-
ter activity and in the gene expression was determined using the
Student’s t test or Multiple Analysis of Variations (MANOVA). The
data are shown as a fold change (mean ± S.D), each of which
represents at least 3 independent experiments that were each
performed triplicate.
3. Results and discussion
3.1. The abundance of human Nrf1/TCF11 is monitored by its putative
O-GlcNAc status
Molecular cloning of human Nrf1 (hNrf1) and its long form
TCF11 reveals both polypeptides comprise 742 and 772 aa, respec-
tively; hNrf1 arises from alternatively splicing of the full-length
mRNA transcript to delete Exon 4 encoding aa 242–271 within
acidic domain 1 (AD1) of TCF11 [44,45]; this region called Neh4L
is highly conserved with the Neh4 transactivation domain of
Nrf2 [39,46]. Almost equal amounts of hNrf1 and TCF11 are
expressed in normal human cell lines, whereas human cancer cell
lines predominantly express hNrf1 rather than TCF11 (data unpub-
lished in our group). However, these two isoforms have similar
transactivation activity mediated primarily by AD1 [47], though
the TAD region of Nrf1 lacks the Neh4 subdomain that is present
in TCF11 (which is absent in the mouse [48,49]).
Herein, we investigated whether the abundance of endogenous
TCF 11/hNrf1 is inﬂuenced by the O-GlcNAc status. Western blot-
ting of total lysates with a speciﬁc antibody against the O-GlcNAc
epitope revealed that treatment of HEK293T cells (that had been
grown in a 5 mmol/L glucose-containing medium enabling the de
novo glycosylation cascade to slow down under the hypoglucose
conditions so that those such as non-glycosylated and/or
de-glycosylated 100kDa Nrf1 were expressed to relative higher
extents, as described previously [37,38]) with 100 lmol/L of
Alloxan (which acts as an OGT-speciﬁc inhibitor to block
O-GlcNAcylation [50,51]) caused a decrease in the O-GlcNAc levels
to 85% of the control value measured from untreated cells
(Fig. 1B, upper panel). Interestingly, the modest inhibition of
O-GlcNAcylation by Alloxan was accompanied by a resulting
1.42-fold increase in the abundance of TCF 11/hNrf1 between
140kDa and 100kDa, in particular both 130kDa and 100kDa pro-
teins (Fig. 1B, middle panel). It should be herein noted that distinct
TCF11/hNrf1 isoforms were separated in the pH 8.9 Laemmli
SDS–PAGE containing 8% polyacrylamide, and therefore their
electrophoretic mobility on the pH 8.9 SDS–PAGE gel is obviously
different from the equivalent mobility exhibited on the pH 7.0
NuPAGE containing 4–12% polyacrylamide [36–38]).
Conversely, 50 lmol/L of PUGNAc (which is the potent inhibitor
of OGA to block de-GlcNAcylation [52,53]) was allowed for treat-
ment of HEK293T cells (that had been grown in a 25 mmol/L
glucose-containing medium facilitating the de novo glycosylation
reaction to be promoted under the hyperglucose condition as
described previously [37,38]), leading to increased levels of
O-GlcNAc by 21% higher than the control level obtained from
untreated cells (Fig. 1C, upper panel). This was accompanied by ele-
vated expression of TCF11/hNrf1 as both major 140kDa and
120kDa proteins, relative to their equivalent abundances under
the hypoglucose conditions so that TCF 11/hNrf1 was principallyexpressed as another major 130kDa and 100kDa proteins (cf.
Fig. 1C, middle panel, with Fig. 1B, middle panel). Intriguingly, the
enhancement of O-GlcNAcylation by PUGNAc appeared to enable
a 25% reduction in the overall expression of TCF11/hNrf1, with
particularly 120kDa isoform to be blocked (Fig. 1C, middle panel,
it should be here noted that the 120kDa of TCF11/hNrf1 was
separated by the pH 8.9 Laemmli SDS–PAGE containing 10%
polyacrylamide, which are proposed to be a processed and/or non
glycosylated/deglycosylated isoform that is sharply distinctive
from the full-length glycoprotein of 120kDa Nrf1 that has been
previously shown to be isolated by the pH 7.0 LDS/NuPAGE gel
containing 4–12% polyacrylamide [36–38]). Collectively, these data
suggest that changes in the putative O-GlcNAc status (of proteins
such as TCF11/hNrf1 and its regulators) monitors the abundance
of the CNC-bZIP protein (and/or its stability).
3.2. Interaction of OGT with Nrf1 enables O-GlcNAcylation of the CNC-
bZIP protein
An amino acid sequence alignment of hNrf1, TCF11 and mouse
Nrf1 (mNrf1) was made by using an programme called T-Coffee
(http://www.ebi.ac.uk/Tools/msa/tcoffee/), revealing that mNrf1
has 97.432% sequence identity with hNrf1 and its long form
TCF11, with the only variable region being presented (Fig. 2A). It
should also be noted that hNrf1-mediated reporter gene activity
appears to be unaffected by lack of aa 242–271 within AD1 of
TCF11, albeit this region contains a nuclear export signal [47,54].
This is consistent with the fact that not a similar form to TCF11
exists in the mouse and thus mNrf1 is essential for exerting its
unique functions to maintain cell homeostasis against various
stresses [21–23]. Thus, an expression construct for mNrf1 has been
employed in transfection experiments with HEK293 cells, in order
to keep a comparison with our previous work focused on the spe-
cies CNC-bZIP factor.
To address the question of what effects the putative O-GlcNAc
status controlled by OGT has on expression of Nrf1 and/or TCF 11,
we next examined whether the CNC-bZIP protein interacts with
OGT enabling it to be O-GlcNAcylated. Firstly, a mixture of either
glutathione S-transferase (GST) or its fusion protein GST-OGT (puri-
ﬁed from IPTG-induced E. coli strain, Fig. 2B, left panel) with total
lysates of HEK293T cells that had been transfected with an expres-
sion construct for mNrf1 tagged with the V5 epitope (mNrf1-V5)
was respectively subjected to pull-down experiments from
glutathione-agarose beads. Subsequently, three fractions of elution
by reduced glutathione were determined by immunoblotting with
antibodies against either GST (Fig. 2B, right upper panel) or V5 epi-
topes (right lower panel). The results revealed that a minor 120kDa
glycoprotein of mNrf1-V5 and its major 95kDa and 85kDa iso-
forms are recovered in the ﬁrst fractional elutant of the GST-OGT
fusion protein rather than the GST moiety, suggesting a possibility
that Nrf1 has a physical interaction with OGT in vitro. Herein, it is
notable that the in vitro non-denatured lysate conditions should
enable the 120kDa mNrf1-V5 deglycosylation to become instead
of amajor95kDa deglycoprotein, followed by an unidentiﬁed pro-
cessing to yield an N-terminally-truncated 85kDa isoform.
Secondly, to examine whether the putative interaction of Nrf1
with OGT occurs in vivo, total lysates of HEK293T cells that had
been grown in 25 mmol/L glucose-medium and co-transfected
with expression constructs for mNrf1-V5 and OGT-Flag (Fig. 2C,
left panel) were subjected to co-immunoprecipitation (CO-IP)
with antibody against the V5 epitope. The results indicate
co-immunoprecipitates of mNrf1-V5 with OGT-Flag, but not a sim-
ilar immunoprecipitate with DOGT [which is an OGT-truncated
mutant lacking the tetraticopeptide repeats 1 (TPR1) to 6 motifs]
was observed (Fig. 2B, right panel). In addition, although that the
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2352 J. Chen et al. / FEBS Letters 589 (2015) 2347–2358hyperglucose condition had been showed to allow mNrf1 to be
expressed as a major 120kDa glycoprotein [37,38], herein the
present expression of 120kDa mNrf1 was repressed by
over-expression of ectopic OGT-Flag (Fig. 2C, left middle panel).
Thirdly, whether co-immunoprecipitates of mNrf1-V5 is
O-GlcNAcylated by OGT was determined next. The HEK293T
cells co-expressing mNrf1-V5 and OGT-Flag had been allowed for
being grown in the hypoglucose medium (i.e. 5 mmol/L
glucose enabling de nevo glycosylation to shut down), before
being added by 5 lmol/L glucosamine (GlcNH2), which serves
as an additional original material of the HBP to recover the
intracellular O-GlcNAcylation catalyzed by OGT). The resultantco-immunoprecipitates with the V5 antibody were visualized by
Western blotting with additional three different antibodies
(Fig. 2D). These results revealed that the co-immunoprecipitates
of mNrf1 and its interacting proteins (e.g. OGT itself) were obvi-
ously modiﬁed through GlcNH2-derived O-GlcNAcylation reaction
with ectopic OGT-Flag and/or endogenous OGT (Fig. 2D, left and
right panels); one of two major electrophoretic bands of OGT pro-
tein is proposed to be a putative O-GlcNAcylation isoform (indi-
cated by G, right upper panel), which was enriched within the
immunoprecipitates more than that visualized by general
Western blotting of total lysates elsewhere. In addition, it is noted
that the hypoglucose conditions enabled mNrf1-V5 to express as a
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transactivation (i.e. mediated by endogenous Nrf1/TCF11 and/or Nrf2) upon siOGT knockdown. A signiﬁcant increase ($P < 0.05, n = 9) is relative to the basal activity
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COS-1 cells [37,38]. Herein, the abundance of the 95kDa mNrf1
was suppressed by either ectopic OGT-Flag or endogenous OGT
isoenzymes (Fig. 2D, left lower panel). Taken together with
LC-MS/MS data (showing that OGT is an Nrf1-interacting protein
[20]), these results indicate that a physical interaction of Nrf1 with
OGT allows the CNC-bZIP protein to be O-GlcNAcylated, resulting
in its destabilization.
3.3. Knockdown of OGT increases expression of Nrf1 and its target
genes
HEK293T cells were transfected with each OGT-targeting siRNA
oligonucleotides (i.e. siOGT-1 and siOGT-2) and subsequently the
expression levels of the O-GlcNAcycling enzyme were examined
by quantitative real-time polymerase chain reaction (qRT-PCR)and Western blotting. The result obtained from qRT-PCR showed
that the expression of OGT mRNA was signiﬁcantly knocked down
by either siOGT-1 or siOGT-2 to approximately 10–25% of the con-
trol value measured obtained from the cells that had been trans-
fected with scrambled siRNA as an internal negative control (i.e.
siNC, with its value of 1 being set) (Fig. 3A). Western blotting
revealed that siOGT-1 knockdown also caused a 36% decrease
in the endogenous OGT protein (Fig. 3B), as accompanied by an
additional 41% reduction in the entire O-GlcNAcylated proteins
(Fig. 3C), when compared with the control siNC levels.
However, relative gene expression of the ARE-driven reporter
PSV40GSTA2-6  ARE-Luciferase was signiﬁcantly increased to
2-fold changes by knockdown of siOGT-1 (Fig. 3D). Further exam-
inations of TCF11/hNrf1 indicated that siOGT-1 knockdown
appeared to cause stabilization of the endogenous CNC-bZIP pro-
teins (particularly 130/140kDa isoforms) such that it was
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being exhibited on SDS–PAGE gels (Fig. 3, E1 and F). Moreover,
endogenous expression of TCF11/Nrf1-target gene products
Lipin1 [55] and GCLM [29,56] was markedly increased by
siOGT-1 knockdown (Fig. 3, E2, E3 and F). Collectively, these results
suggest that knockdown of OGT appears to promote stabilization of
hNrf1/TCF11, leading to an increase in expression of its
downstream genes.
3.4. Over-expression of OGT reduces the abundance of Nrf1 and its
transactivation activity
To further determine the putative effect of OGT on Nrf1/TCF11,
we transfected an expression construct for either the C-terminally
ﬂagged OGT (i.e. OGT-Flag) or enhanced green ﬂuorescent protein
(EGFP, as an internal control) into HEK293T cells. Western blotting
of the cell lysates showed that over-expression of ectopic OGT-Flag
protein caused a 3.14-fold increase in the entire O-GlcNAcylation
mediated by this enzyme, when compared with the control value
of 1.00 that mediated by the endogenous OGT enzyme (Fig. 4A,
upper and middle panels and 4C). By comparison with
siOGT-mediated blockage of O-GlcNAcylation, the pattern of
O-GlcNAcylated proteins decreased by siOGT-1 (Fig. 3C) is mark-
edly distinctive from that of the OGT-elevated O-GlcNAcylated pro-
teins (including TCF11/hNrf1 and OGT itself that were deduced as
major speciﬁc glycosylated proteins) (Fig. 4A, middle panel).
Intriguingly, the ectopic OGT-Flag over-expression led to an
obvious reduction in the abundance of endogenous TCF11/hNrf1
proteins (particularly130kDa and 140kDa) to 57% of the control
levels measured from the cells that had been transfected with an
EGFP-expression construct (Fig. 4B, upper panel and 4C). Further,
luciferase reporter assays also revealed that a signiﬁcant decrease
in transcriptional expression of the PSV40GSTA2-6  ARE-Luc
reporter gene from 60- to 10-fold changes was resulted fromOGT-Flag over-expression (Fig. 4D). Overall, these data indicate
that forced expression of OGT results in marked decreases in the
abundance of endogenous hNrf1/TCF11 and its transactivation
activity to mediate ARE-driven gene expression.
3.5. The turnover of Nrf1 is regulated by OGT-directed O-
GlcNAcylation
The above-described results raise a question of why the poten-
tial O-GlcNAcylation of Nrf1/TCF11 by OGT causes a decrease in the
amount of the CNC-bZIP factor and its transcriptional activity.
Although it is clear that the stability of Nrf1/TCF11 is regulated
through different ubiquitin (Ub) ligases Hrd1, SCFb-TrCP and
SCFFbw7 targeting the CNC-bZIP protein to distinct degradation
pathways [22,57,58], it is unknown of whether ubiquitination of
Nrf1/TCF 11 is regulated by its O-GlcNAcylation status. Herein, in
order to address whether or how O-GlcNAcylation of Nrf1/TCF11
monitors the protein stability through the ubiquitin-proteasomal
degradation pathway, three expression constructs for both mNrf1
and Ub-HA (i.e. Ub tagged by HA C-terminally) together with either
OGT-Flag or EGFP (as an internal control) were co-transfected into
HEK293T cells (Fig. 5A). Western blotting of the total cell lysates
showed that over-expression of ectopic OGT-Flag and Ub-HA did
cause an obvious increase in the amount of total ubiquitinated pro-
teins, including the enzyme OGT itself (Fig. 5A, upper and lower
panels); this was, however, accompanied by decreased expression
level of the 120kDa mNrf1 glycoprotein (middle panel). Taken
together with other MG132-based experimental evidence showing
that the turnover of Nrf1/TCF11 occurs via Hrd1-, SCFb-TrCP- and/or
SCFFBW7-directed ubiquitin-mediated protein degradation path-
ways [22,57–59], it is therefore postulated that O-GlcNAcylation
of mNrf1 by OGT enables destabilization of the CNC-bZIP protein,
possibly via the ubiquitin-proteasomal degradation pathway,
albeit detailed mechanistic studies are required.
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J. Chen et al. / FEBS Letters 589 (2015) 2347–2358 2355Next, we examined whether the role of OGT in the negative reg-
ulation of Nrf1 is inﬂuenced by the concentration of glucose. When
HEK293T cells had been grown in a 25-mmol/L hyperglucose med-
ium enabling de novo metabolism to product a certain amount of
the major substrate UDP-GlcNAc required for the OGT-catalyzed
O-GlcNAcylation, over-expression of OGT-Flag caused signiﬁcant
decreases in the abundances of the major ectopic mNrf1-V5 pro-
teins (between 120kDa and 95kDa) and the minor endogenoushNrf1/TCF11 (of between 140kDa and 100kDa) (Fig. 5B, two
central lanes in upper and middle panels). Conversely, expression
of these CNC-bZIP proteins (particularly of 95kDa) appeared to
be markedly increased to 1.87-fold, even though ectopic
OGT-Flag expression was retained in the HEK293T cells that had
been grown in a 5-mmol/L hypoglucose medium, in which the
yield of UDP-GlcNAc was reduced leading to elimination of the
OGT-catalyzed O-GlcNAcylation. Further examinations revealed
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to 1.69-fold expression in the cells that had been co-transfected
with a construct for the DOGT mutant (lacking its TPR1–6 motifs)
(Fig. 5C, upper panel), and the recovery was not associated with the
abundance of DOGT expressed as a major truncated protein,
together with a relative minor and slower glycosylated isoform,
being displayed on the pH 8.9 SDS–PAGE gel containing 6% poly-
acrylamide (Fig. 5C, middle panel). Taken together with the above
data (shown in Figs. 2–4), these results suggest that the TPR1–6
region of OGT enables the O-GlcNAc enzyme to interact with
Nrf1/TCF11, allowing the latter CNC-bZIP protein to be modiﬁed
by O-GlcNAcylation.
Subsequently, the inhibitory effect of OGT on the stability of
Nrf1/TCF 11 and its turnover was further determined by cyclohex-
imide (CHX, that inhibits biosynthesis of nascent polypeptides)
chase experiments of HEK293T cells that had been transfected
with siOGT or siNC before being treated with the chemical
(100 lg/ml) in medium containing 25 mM glucose. After knock-
down of OGT, its residual protein became fainter as the chase time
was extended to 4 h after treatment with CHX (Fig. 5D, middle
panel). By contrast, the endogenous hNrf1/TCF11 expression was
increased by siOGT knockdown, when compared with the control
siNC levels (upper panels). Further observations revealed that the
abundance of the longer hNrf1/TCF 11 proteins was signiﬁcantly
decreased following 1 h-treatment of siNC-transfected cells with
CHX, and the chemical treatment of siOGT-transfected cells only
caused the turnover of hNrf1/TCF11 to be slightly prolonged to
2 h (Fig. 5D, left upper panel). However, the half-life (estimated
50 min) of the existing major longer CNC-bZIP proteins after
treatment with CHX appeared to be unaltered by knockdown of
siOGT (Fig. 5E), although the stoichiometric graphs and lines
presented a different tendency to reveal the turnover of
hNrf1/TCF11 after knockdown of siOGT when compared with thesiNC control levels. Collectively, these data indicate that OGT
has a negative capability to decrease basal expression of
hNrf1/TCF11, but the detailed mechanism by which the process
of the proteolytic degradation of the existing CNC-bZIP proteins
is regulated by the O-GlcNAcylation enzyme is not well under-
stood. Intriguingly, siOGT knockdown rendered the enhanced
hNrf1/TCF11 protein to exhibit a slower mobility during
electrophoresis than the corresponding control case of siNC
(Fig. 5D, cf. right 5 lanes with left 5 lanes). Together with OGT
over-expression data, this ﬁnding leads us to surmise that OGT
could act as an indirect regulator to promote ubiquitin-mediated
degradation, and might also serve as a direct functional protease
as described for the processing of HCF1 [19], although these events
require further investigation.
3.6. O-GlcNAcylation of Nrf1 is associated with its serine-rich portion
of the PEST2 sequence
The C-terminal enzymatic activity of OGT to catalyze addition of
O-GlcNAc to cognate substrate polypeptides is regulated primarily
by its N-terminal TPR domain, that dictates different features of all
three spliced isoforms of 116-, 103- and 74.5kDa and can also pro-
vide a scaffold structure enabling the enzyme to physically interact
with its substrate protein [16,17]. As described above, a potential
interaction of OGT with Nrf1 is likely to be dictated by its TPR
domain, allowing the CNC-bZIP protein to be O-GlcNAcylated
(Fig. 2). In turn, O-GlcNAcylation of hNrf1/TCF11 by OGT enables
down-regulation of its basal expression and/or its protein stability,
whilst removal of the TPR1–6 motifs causes a recovery from
the inhibitory effects of OGT on Nrf1 (Figs. 3–5). Herein, to
provide a better understanding of which regions within Nrf1 are
engaged in association with OGT-directed O-GlcNAcylation, we
performed further experiments of HEK293T cells that had been
J. Chen et al. / FEBS Letters 589 (2015) 2347–2358 2357co-transfected with expression constructs for each of wild-type
mNrf1 and its mutants lacking various lengths of the protein,
together with OGT or the EGFP control, followed by Western blot-
ting to examine which mutants enable mNrf1 to be recovered from
the inhibitory effect of OGT on the CNC-bZIP factor.
By comparison of the intensity ratios ofWestern blots for Nrf1 or
its mutant proteins in OGT + Nrf1-expressing cells to their corre-
sponding yields from EGFP + Nrf1-expressing cells (Fig. 6, on the
bottom of the upper panels), the results revealed that deletion of
the serine-repeats (SR) domain (aa 454–488, lanes #8 with
1.00/1.35), the SR-adjoining PEST2 sequence (aa 456–519, lanes #7
with 1.00/1.32) or the PEST2-containing large region (aa 403–506,
lanes #10 with 1.00/3.68) from mNrf1, but not removal of its
Neh6L domain (aa 489–580, lanes #9), caused a marked
recovery from the putative inhibitory effect of OGT-directed
O-GlcNAcylation on the protein, leading to an increase in the abun-
dance of the major longer isoform of each of Nrf1 mutants (as indi-
cated⁄), when compared to thewild-type protein with the 1.00:0.79
ratio of its expression with OGT to its production in the absence of
the enzyme (Fig. 6, lanes #1). This ﬁnding suggests that the SR por-
tion of the PEST2 degron appears to be associated with the putative
O-GlcNAcylation of wild-type mNrf1 by OGT, although the detailed
mechanism remains to be explored. In addition, a modest recovery
of mNrf1 from OGT-mediated inhibition was observed upon dele-
tion of the N-terminal 191-aa region covering both NTD and AD1
of mNrf1 (Fig. 6, lanes #3 with a ratio of 1.00/1.24), but not removal
of its N-terminal 80-aa small region (lanes #2), hence implying that
a region between aa 81–291 may also be involved in OGT-directed
O-GlcNAcylation of Nrf1. Conversely, a loss of the NST domain (aa
299–400, lanes #4 with 1.00/0.37), but not of the AD2 regions (aa
403–455, lanes #5 & 6), caused an apparent enhancement in
OGT-mediated destabilization of the Nrf1D299440 mutant by
42%, when compared with the wild-type Nrf1 protein.
Furthermore, our previous work has showed that the NST domain
of Nrf1 is N-glycosylated and also enables it to be anchored within
the ER lumen and, hitherto demonstrated that the process controls
its topovectorial repartitioning out of the organelle [34–39].
Together, our ﬁndings suggest that the NST glycodomain of Nrf1
contributes to stabilization of its wild-type protein possibly
through a mechanism that negatively monitors the repositioning
of NST-ﬂanking regions (aa 454–488 and 81–291) from the ER
lumen into the cyto/nucleoplasmic compartments, such that both
regions would be allowed for association with the OGT-mediated
event for O-GlcNAcylation. In addition, O-GlcNAcylation of Nrf1
might have a putative effect on its phosphodegrons that were iden-
tiﬁed to be located within NST-adjoining regions and mediated by
glycogen synthase kinase-3b (GSK-3b) [57,59], leading to the
CNC-bZIP protein degradation by SCFb-TrCP- or SCFFBW7-directed
ubiquitin-mediated pathways.
In summary, our present work reveals that: (i) Nrf1 enables an
interaction with OGT, and the co-immunoprecipitates of the
CNC-bZIP protein is O-GlcNAcylated together with the enzyme
OGT, but without its mutant lacking the TPR1–6 region of OGT;
(ii) OGT-directed O-GlcNAcylation of Nrf1 contributes to negative
regulation of basal expression of the CNC-bZIP factor, its protein
stability and its transactivation activity to down-regulate target
genes; (iii) The negative regulation of Nrf1 by OGT is attributable
to increased ubiquitination of the CNC-bZIP protein inasmuch as
its turnover is promoted; and (iv) Within Nrf1, the SR portion
(aa 454–488) of the putative PEST2 degron (along with a
region between aa 81–291) may be involved in putative
O-GlcNAcylation of the protein by OGT. Overall, Nrf1 is negatively
regulated by its O-GlcNAcylation status that is controlled by OGT,
which is dependent on changes in the glucose concentrations (in
which both OGT glycosylation and its enzymatic activity are also
regulated). However, it is required to determine whether andhow the putative O-GlcNAcylation of Nrf1 monitors the selective
processing of the CNC-bZIP factor to yield distinct isoforms and/or
its topovectorial repositioning to dislocate from the ER to the
nucleus, enabling it to ﬁne-tune ARE-driven gene expression.
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